In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis
Open Access
- 12 March 2019
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 21 (1) , 72
Abstract
Resolvin D1 (RvD1), an important member of resolvins, exerts a wide spectrum of biological effects, including resolution of inflammation, tissue repair, and preservation of cell viability. The aim of the present study is to investigate the anti-arthritic potential and clarify the bone protective actions of RvD1 in vitro and in vivo. RAW264.7 cells were treated with 50 ng/ml LPS for 72 h in the presence or absence of RvD1 (0–500 nM). Primary human monocytes were treated with M-CSF + RANKL for 14 days ± RvD1 (0–500 nM) with or without siRNA against RvD1 receptor FPR2. Expressions of inflammatory mediators, degrading enzymes, osteoclasts (OC) formation, and bone resorption were analyzed. The therapeutic effect of RvD1 (0–1000 ng) was carried out in murine collagen antibody-induced arthritis. Arthritis scoring, joint histology, and inflammatory and bone turnover markers were measured. RvD1 is not toxic and inhibits OC differentiation and activation. It decreases bone resorption, as assessed by the inhibition of TRAP and cathepsin K expression, hydroxyapatite matrix resorption, and bone loss. In addition, RvD1 reduces TNF-α, IL-1β, IFN-γ, PGE2, and RANK and concurrently enhances IL-10 in OC. Moreover, in arthritic mice, RvD1 alleviates clinical score, paw inflammation, and bone and joint destructions. Besides, RvD1 reduces inflammatory mediators and markedly decreases serum markers of bone and cartilage turnover. Our results provide additional evidence that RvD1 plays a key role in preventing bone resorption and other pathophysiological changes associated with arthritis. The study highlights the clinical relevance of RvD1 as a potential compound for the treatment of inflammatory arthritis and related bone disorders.Keywords
Funding Information
- Institute of Musculoskeletal Health and Arthritis (MOP-130293)
- Fonds de Recherche en Orthopédie-HSCM
This publication has 50 references indexed in Scilit:
- Resolvin D1 Polarizes Primary Human Macrophages toward a Proresolution Phenotype through GPR32The Journal of Immunology, 2016
- Resolvin D1, resolvin D2 and maresin 1 activate the GSK3β anti-inflammatory axis in TLR4-engaged human monocytesInnate Immunity, 2016
- Proresolving Lipid Mediators and Mechanisms in the Resolution of Acute InflammationImmunity, 2014
- Resolvin D1 and Its Precursor Docosahexaenoic Acid Promote Resolution of Adipose Tissue Inflammation by Eliciting Macrophage Polarization toward an M2-Like PhenotypeThe Journal of Immunology, 2011
- Resolvins and protectins: Natural pharmacophores for resolution biologyProstaglandins, Leukotrienes and Essential Fatty Acids, 2010
- Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoidsArthritis Research & Therapy, 2009
- Type II collagen autoimmunity in a mouse model of human rheumatoid arthritisAutoimmunity Reviews, 2007
- Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis.2007
- Osteoarthritis cartilage histopathology: grading and stagingOsteoarthritis and Cartilage, 2006
- Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factorArthritis & Rheumatism, 2000